{{Rsnum
|rsid=420259
|Gene=PALB2
|Chromosome=16
|position=23622705
|Orientation=minus
|GMAF=0.3434
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PALB2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 4.4 | 31.0 | 64.6
| HCB | 15.3 | 48.2 | 36.5
| JPT | 9.7 | 48.7 | 41.6
| YRI | 20.4 | 51.7 | 27.9
| ASW | 14.0 | 45.6 | 40.4
| CHB | 15.3 | 48.2 | 36.5
| CHD | 13.8 | 48.6 | 37.6
| GIH | 9.9 | 38.6 | 51.5
| LWK | 24.5 | 44.5 | 30.9
| MEX | 6.9 | 36.2 | 56.9
| MKK | 32.7 | 49.4 | 17.9
| TSI | 2.9 | 43.1 | 53.9
| HapMapRevision=28
}}
Linked to [[bipolar disorder]] in one of the most comprehensive studies in 2007. Risk allele with reference to dbSNP orientation is reported to be (T), with either one or two copies leading to an odds ratio of 2 (CI 1.6-2.7). {{PMID|17554300|OA=1
}} 

Some replications, but in 2011 [[23andMe]] published as failed to replicate in {{doi|10.1371/journal.pone.0023473}}

{{GWAS Summary
|SNP=rs420259
|PubMedID=17554300
|Condition=Bipolar disorder
|Gene=PALB2,NDUFAB1,DCTN5
|Risk Allele=T
|pValue=6.00E-008
|OR=2.08
|95CI=1.60-2.71
|OA=1
}}

{{omim
|desc=MAJOR AFFECTIVE DISORDER 4; MAFD4
|id=611247
|rsnum=420259
}}

{{PharmGKB
|RSID=rs420259
|Name_s=
|Gene_s=PALB2
|Feature=
|Evidence=PubMed ID:17554300; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (Initial Sample Size: 1,868 cases, 2,938 controls; Replication Sample Size: NR; Risk Allele: rs420259-A). This variant is associated with bipolar disorder.
|Drugs=
|Drug Classes=
|Diseases=Bipolar Disorder
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356654
}}

{{PMID Auto
|PMID=20872766
|Title=Association analysis of PALB2 and BRCA2 in bipolar disorder and schizophrenia in a scandinavian case-control sample
}}

{{PMID Auto GWAS
|PMID=21254220
|Trait=None
|Title=Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder.
|RiskAllele=
|Pval=9E-9
|OR=None
|ORtxt=None
|OA=1
}}

{{PMID|18224312|OA=1
}} Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

{{PMID|19308021|OA=1
}} Findings from bipolar disorder genome-wide association studies replicate in a Finnish bipolar family-cohort.

{{PMID|19931040|OA=1
}} Simultaneous genotype calling and haplotype phasing improves genotype accuracy and reduces false-positive associations for genome-wide association studies.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs420259
|overall_frequency_n=38
|overall_frequency_d=126
|overall_frequency=0.301587
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=30
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}